Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2017 Apr 26

PMID 28441353

Citations 47

Authors

Yasuto Araki

Toshihide Mimura

Affiliations

Soon will be listed here.

Abstract

Matrix metalloproteinases (MMPs) are implicated in the degradation of extracellular matrix (ECM). Rheumatoid arthritis (RA) synovial fibroblasts (SFs) produce matrix-degrading enzymes, including MMPs, which facilitate cartilage destruction in the affected joints in RA. Epigenetic mechanisms contribute to change in the chromatin state, resulting in an alteration of gene transcription. Recently, MMP gene activation has been shown to be caused in RASFs by the dysregulation of epigenetic changes, such as histone modifications, DNA methylation, and microRNA (miRNA) signaling. In this paper, we review the role of MMPs in the pathogenesis of RA as well as the disordered epigenetic mechanisms regulating MMP gene activation in RASFs.

Citing Articles

Regulation of cytokine and chemokine expression by histone lysine methyltransferase MLL1 in rheumatoid arthritis synovial fibroblasts.

Okamoto K, Araki Y, Aizaki Y, Tanaka S, Kadono Y, Mimura T Sci Rep. 2024; 14(1):10610.

PMID: 38719857 PMC: 11078978. DOI: 10.1038/s41598-024-60860-7.

Unveiling the Nexus: Cellular Metabolomics Unravels the Impact of Estrogen on Nicotinamide Metabolism in Mitigating Rheumatoid Arthritis Pathogenesis.

Malik S, Chakraborty D, Agnihotri P, Kumar V, Biswas S Metabolites. 2024; 14(4).

PMID: 38668342 PMC: 11052502. DOI: 10.3390/metabo14040214.

Extracellular vesicles as tools and targets in therapy for diseases.

Kumar M, Baba S, Sadida H, Al Marzooqi S, Jerobin J, Altemani F Signal Transduct Target Ther. 2024; 9(1):27.

PMID: 38311623 PMC: 10838959. DOI: 10.1038/s41392-024-01735-1.

Epigenetic Dysregulation in the Pathogenesis of Systemic Lupus Erythematosus.

Araki Y, Mimura T Int J Mol Sci. 2024; 25(2).

PMID: 38256093 PMC: 10816225. DOI: 10.3390/ijms25021019.

Evaluation of anti-inflammatory and immunomodulatory potential of Lawsone (2-hydroxy-1,4-naphthoquinone) using pre-clinical rodent model of rheumatoid arthritis.

Sattar S, Shabbir A, Shahzad M, Akhtar T, Anjum S, Bourhia M Front Pharmacol. 2023; 14:1279215.

PMID: 37900171 PMC: 10603269. DOI: 10.3389/fphar.2023.1279215.

References

Choy E, Hazleman B, Smith M, Moss K, Lisi L, Scott D . Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford). 2002; 41(10):1133-7. DOI: 10.1093/rheumatology/41.10.1133. View

Maini R, St Clair E, Breedveld F, Furst D, Kalden J, Weisman M . Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 2000; 354(9194):1932-9. DOI: 10.1016/s0140-6736(99)05246-0. View

Shofuda K, Yasumitsu H, Nishihashi A, Miki K, Miyazaki K . Expression of three membrane-type matrix metalloproteinases (MT-MMPs) in rat vascular smooth muscle cells and characterization of MT3-MMPs with and without transmembrane domain. J Biol Chem. 1997; 272(15):9749-54. DOI: 10.1074/jbc.272.15.9749. View

Emery P, Breedveld F, Hall S, Durez P, Chang D, Robertson D . Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008; 372(9636):375-82. DOI: 10.1016/S0140-6736(08)61000-4. View

Lipsky P, van der Heijde D, St Clair E, Furst D, Breedveld F, Kalden J . Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000; 343(22):1594-602. DOI: 10.1056/NEJM200011303432202. View

van Gaalen F, van Aken J, Huizinga T, Schreuder G, Breedveld F, Zanelli E . Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum. 2004; 50(7):2113-21. DOI: 10.1002/art.20316. View

Cutolo M, Accardo S . Sex hormones, HLA and rheumatoid arthritis. Clin Exp Rheumatol. 1991; 9(6):641-6. View

Hutchinson D, Shepstone L, Moots R, Lear J, Lynch M . Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA. Ann Rheum Dis. 2001; 60(3):223-7. PMC: 1753588. DOI: 10.1136/ard.60.3.223. View

Ciechanover A . Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol. 2005; 6(1):79-87. DOI: 10.1038/nrm1552. View

10.

Breedveld F, Weisman M, Kavanaugh A, Cohen S, Pavelka K, van Vollenhoven R . The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had.... Arthritis Rheum. 2005; 54(1):26-37. DOI: 10.1002/art.21519. View

11.

Wang Z, Zang C, Rosenfeld J, Schones D, Barski A, Cuddapah S . Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008; 40(7):897-903. PMC: 2769248. DOI: 10.1038/ng.154. View

12.

Moreland L, Schiff M, Baumgartner S, Tindall E, Fleischmann R, Bulpitt K . Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999; 130(6):478-86. DOI: 10.7326/0003-4819-130-6-199903160-00004. View

13.

Araki Y, Mimura T . The Histone Modification Code in the Pathogenesis of Autoimmune Diseases. Mediators Inflamm. 2017; 2017:2608605. PMC: 5239974. DOI: 10.1155/2017/2608605. View

14.

Ghildiyal M, Zamore P . Small silencing RNAs: an expanding universe. Nat Rev Genet. 2009; 10(2):94-108. PMC: 2724769. DOI: 10.1038/nrg2504. View

15.

Ni X, Xia T, Zhao Y, Zhou W, Wu N, Liu X . Downregulation of miR-106b induced breast cancer cell invasion and motility in association with overexpression of matrix metalloproteinase 2. Cancer Sci. 2013; 105(1):18-25. PMC: 4317878. DOI: 10.1111/cas.12309. View

16.

Keystone E . Treatments no longer in development for rheumatoid arthritis. Ann Rheum Dis. 2002; 61 Suppl 2:ii43-5. PMC: 1766723. DOI: 10.1136/ard.61.suppl_2.ii43. View

17.

Sweeney S, Hammaker D, Boyle D, Firestein G . Regulation of c-Jun phosphorylation by the I kappa B kinase-epsilon complex in fibroblast-like synoviocytes. J Immunol. 2005; 174(10):6424-30. DOI: 10.4049/jimmunol.174.10.6424. View

18.

Yan C, Boyd D . Regulation of matrix metalloproteinase gene expression. J Cell Physiol. 2006; 211(1):19-26. DOI: 10.1002/jcp.20948. View

19.

Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z . Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2010; 62(4):917-28. DOI: 10.1002/art.27348. View

20.

Cantorna M, Hayes C, DeLuca H . 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr. 1998; 128(1):68-72. DOI: 10.1093/jn/128.1.68. View